haloperidol has been researched along with Blepharoptosis in 24 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Blepharoptosis: Drooping of the upper lid due to deficient development or paralysis of the levator palpebrae muscle.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a separate test, muscular rigidity is induced by the opioid, fentanyl, and subsequently, test compounds are assessed for their ability to reverse muscular rigidity." | 1.28 | An in vivo alpha-2 assay reversal of opioid-induced muscular rigidity and neuroleptic-induced ptosis. ( Benvenga, MJ; Capacchione, JF; Del Vecchio, RA; Jerussi, TP, 1992) |
| "Severe vomiting was evoked by Apo in dogs, but not by Eph even when lethal dose (20 mg." | 1.28 | [Comparison of central stimulating effects between ephedrine and apomorphine]. ( Li, BH; Li, Q, 1991) |
| "Methylphenidate was weakly effective against clonazepam and haloperidol but inactive versus CER." | 1.27 | Neuroleptic-like effects of ceruletide and cholecystokinin octapeptide: interactions with apomorphine, methylphenidate and picrotoxin. ( Zetler, G, 1983) |
| "Thus, catalepsy is a robust endogenously regulated circadian response that is only slowly influenced by altered lighting conditions which dissociate this rhythm of neuroleptic response from that of spontaneous general arousal." | 1.26 | Circadian changes in behavioral effects of haloperidol in rats. ( Baldessarini, RJ; Campbell, A, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (75.00) | 18.7374 |
| 1990's | 5 (20.83) | 18.2507 |
| 2000's | 1 (4.17) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maryanoff, BE | 1 |
| McComsey, DF | 1 |
| Gardocki, JF | 1 |
| Shank, RP | 1 |
| Costanzo, MJ | 1 |
| Nortey, SO | 1 |
| Schneider, CR | 1 |
| Setler, PE | 1 |
| Zetler, G | 2 |
| Campbell, A | 3 |
| Baldessarini, RJ | 3 |
| Subarnas, A | 1 |
| Tadano, T | 1 |
| Oshima, Y | 1 |
| Kisara, K | 1 |
| Ohizumi, Y | 1 |
| El Yacoubi, M | 1 |
| Ledent, C | 1 |
| Parmentier, M | 1 |
| Bertorelli, R | 1 |
| Ongini, E | 1 |
| Costentin, J | 2 |
| Vaugeois, JM | 1 |
| Niemegeers, CJ | 7 |
| Laduron, PM | 1 |
| Pedigo, NW | 1 |
| Schallert, T | 1 |
| Overstreet, DH | 1 |
| Ling, NC | 1 |
| Ragan, P | 1 |
| Reisine, TD | 1 |
| Yamamura, HI | 1 |
| Ito, K | 1 |
| Nurimoto, S | 1 |
| Shintomi, K | 1 |
| Kowa, Y | 1 |
| Yamamura, M | 1 |
| Ishida, R | 1 |
| Janssen, PA | 5 |
| Schellekens, KH | 2 |
| Lenaerts, FM | 2 |
| Wauquier, A | 2 |
| Benvenga, MJ | 1 |
| Del Vecchio, RA | 1 |
| Capacchione, JF | 1 |
| Jerussi, TP | 1 |
| Li, Q | 1 |
| Li, BH | 1 |
| Duterte-Boucher, D | 1 |
| Kamenka, JM | 1 |
| Rao, KV | 2 |
| Puri, VN | 2 |
| el-Sawaf, HA | 1 |
| Diwan, PK | 1 |
| Alvarez, FM | 1 |
| Dresse, A | 1 |
| Pinchard, A | 1 |
| Schaper, WK | 1 |
| van Nueten, JM | 1 |
| Verbruggen, FJ | 3 |
| Borgman, RJ | 1 |
| Baylor, MR | 1 |
| McPhillips, JJ | 1 |
| Stitzel, RE | 1 |
| Lal, H | 1 |
| Cools, AR | 1 |
1 review available for haloperidol and Blepharoptosis
| Article | Year |
|---|---|
Pharmacology and biochemistry of haloperidol.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Blepharoptosis; Bra | 1976 |
23 other studies available for haloperidol and Blepharoptosis
| Article | Year |
|---|---|
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
Topics: Animals; Antidepressive Agents; Blepharoptosis; Brain; Catecholamines; Chemical Phenomena; Chemistry | 1987 |
Clonidine and yohimbine separate the sedation and the ptosis caused by cholecystokinin octapeptide and ceruletide.
Topics: Animals; Apomorphine; Blepharoptosis; Catalepsy; Ceruletide; Clonidine; Drug Antagonism; Haloperidol | 1984 |
Neuroleptic-like effects of ceruletide and cholecystokinin octapeptide: interactions with apomorphine, methylphenidate and picrotoxin.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Blepharoptosis; Body Temperature; Ceru | 1983 |
Effects of maturation and aging on behavioral responses to haloperidol in the rat.
Topics: Aging; Animals; Behavior, Animal; Blepharoptosis; Dose-Response Relationship, Drug; Haloperidol; Mal | 1981 |
Circadian changes in behavioral effects of haloperidol in rats.
Topics: Animals; Behavior, Animal; Blepharoptosis; Catalepsy; Circadian Rhythm; Dose-Response Relationship, | 1982 |
Tolerance to behavioral effects of haloperidol.
Topics: Animals; Behavior, Animal; Blepharoptosis; Body Weight; Catalepsy; Drug Tolerance; Growth; Haloperid | 1981 |
Pharmacological properties of beta-amyrin palmitate, a novel centrally acting compound, isolated from Lobelia inflata leaves.
Topics: Animals; Antidepressive Agents; Apomorphine; Blepharoptosis; Catalepsy; Central Nervous System; Dose | 1993 |
Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blepharoptosis; Disease Models, Animal; Dopamine A | 2001 |
Inhibition of in vivo 3H-spiperone binding by the proposed antipsychotic Des-Tyr1-gamma-endorphin.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Blepharoptosis; Brain; Butyrophenones; Catalepsy; E | 1979 |
[Pharmacological studies of an antipschotic agent, penfluridol. (1). The central pharmacological actions].
Topics: Agonistic Behavior; Animals; Apomorphine; Avoidance Learning; Blepharoptosis; Body Temperature; Cata | 1976 |
Clopimozide (R 29 764), a new highly potent and orally long-acting neuroleptic of the diphenylbutylpiperidine series.
Topics: Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Benzimidazoles; Blepharoptosis; Body Tem | 1975 |
An in vivo alpha-2 assay reversal of opioid-induced muscular rigidity and neuroleptic-induced ptosis.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Blepharoptosis; Drug Evaluation, P | 1992 |
[Comparison of central stimulating effects between ephedrine and apomorphine].
Topics: Animals; Apomorphine; Blepharoptosis; Catalepsy; Ephedrine; Haloperidol; Male; Mice; Motor Activity; | 1991 |
Comparison of the effects of three indirect dopamine agonists, GK 13, GBR 12783 and dexamphetamine on behavioural tests involving central catecholaminergic transmissions.
Topics: Animals; Behavior, Animal; Blepharoptosis; Body Temperature; Brain Chemistry; Catecholamines; Dextro | 1990 |
Further studies on the neuroleptic profile of manassantin A.
Topics: Adenylyl Cyclase Inhibitors; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Binding, | 1990 |
Preliminary evaluation of manassantin A, a potential neuroleptic agent from Saururus cernuus.
Topics: Amphetamine; Animals; Antipsychotic Agents; Blepharoptosis; Body Temperature; Catalepsy; Furans; Hal | 1987 |
Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. I. The comparative pharmacology of pimozide, haloperidol, and chlorpromazine.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Benzimidazoles; Blepharoptosis; Body Temperatur | 1968 |
Bromoperidol, a new potent neuroleptic of the butyrophenone series. Comparative pharmacology of bromoperidol and haloperidol.
Topics: Administration, Oral; Amphetamine; Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Bleph | 1974 |
Alpha-methyldopamine derivatives. Synthesis and pharmacology.
Topics: Animals; Apomorphine; Blepharoptosis; Body Temperature; Depression, Chemical; Dihydroxyphenylalanine | 1974 |
Differential antagonism by naloxone of inhibitory effects of haloperidol and morphine on brain self-stimulation.
Topics: Animals; Behavior, Animal; Blepharoptosis; Brain; Catalepsy; Catatonia; Electric Stimulation; Electr | 1974 |
The function of dopamine and its antagonism in the caudate nucleus of cats in relation to the stereotyped behaviour.
Topics: Animals; Apomorphine; Behavior, Animal; Blepharoptosis; Cats; Caudate Nucleus; Dextroamphetamine; Do | 1971 |
The influence of various neuroleptic drugs on shock avoidance responding in rats. II. Nondiscriminated Sidman avoidance procedure with alternate reinforcement and extinction periods and analysis of the interresponse times (IRT's).
Topics: Animals; Antidepressive Agents; Avoidance Learning; Benperidol; Blepharoptosis; Butyrophenones; Cata | 1969 |
The influence of various neuroleptic drugs on noise escape response in rats.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Benperidol; Blepharoptosis; Butyrophenones; Cata | 1970 |